A combination formulation containing an SGLT-2 inhibitor and a DPP-4 inhibitor for the prevention or treatment of vascular stenosis or valvular stenosis.

A combination of SGLT-2 and DPP-4 inhibitors addresses the lack of drug therapies for vascular and valvular stenosis by synergistically inhibiting calcification, effectively reducing stenosis progression and restoring tissue health.

JP2026539044APending Publication Date: 2026-11-19レッドエンビア カンパニー リミテッド
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2026524547
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-23
Filing Date
2024-10-24
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There are no effective non-invasive drug therapies available to treat vascular stenosis or valvular stenosis caused by calcification, which can lead to complications such as hypertension, heart failure, and valvular heart disease.

Method used

A combination formulation of an SGLT-2 inhibitor, such as gliflozin, and a DPP-4 inhibitor, such as gliptin, is used to inhibit calcification of blood vessels and valves, offering a synergistic effect in preventing or treating vascular and valvular stenosis.

Benefits of technology

The combination therapy effectively reduces calcification progression and severity, slowing down the development of stenosis and restoring tissue to a normal state, providing a more effective treatment than either inhibitor alone.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026539044000001_ABST
    Figure 2026539044000001_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition comprising a gliflozin-type drug and a gliptin-type drug for preventing or treating vascular stenosis or valvular stenosis. When the gliflozin-type drug and the gliptin-type drug according to the present invention are administered simultaneously, calcification is synergistically reduced compared to the administration of each drug alone, making the composition according to the present invention highly effective for vascular stenosis or valvular stenosis.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present invention relates to a pharmaceutical composition for preventing or treating vascular stenosis or valvular stenosis, comprising a SGLT-2 (sodium-glucose cotransporter 2) inhibitor such as a gliflozin series drug and a DPP-4 (dipeptidyl peptidase-4) inhibitor.

BACKGROUND ART

[0002] Aortic stenosis is a disorder or pathological condition in which the aortic valve, which is the valve at the site where blood flows from the left ventricle into the aorta, does not open properly during contraction of the left ventricle. The pathophysiology of aortic stenosis is complex, involving numerous pathological processes such as lipid retention, oxidation, chronic inflammation, fibrosis, and calcification. In particular, the condition or disorder in which calcification occurs in the aortic valve is known as calcific aortic valve disease (CAVD). Currently, there are no approved drug therapies specifically dedicated to aortic stenosis or CAVD. Therefore, the only treatment options are surgical aortic valve implantation (SAVI) and transcatheter aortic valve implantation (TAVI) via a non-surgical catheter-based approach.

[0003] Cardiovascular calcification contributes to the exacerbation of hypertension, heart failure, acute coronary syndromes, and valvular heart disease, and causes various complications. Calcification may occur independently, or may occur together with fibrosis. Numerous epidemiological studies have demonstrated that vascular calcification independently increases mortality. Vascular calcification occurs via mechanisms similar to those of normal fetal bone formation programs or post-fracture bone formation programs, and is activated in old age, diabetes, chronic renal failure, and chronic inflammatory diseases. The inflammatory response promotes mineral loss from bone, and the released minerals are phagocytosed by abnormal vascular endothelial cells. On the other hand, calcification also occurs in the heart valves, and calcification in heart valves, particularly the aortic valve, causes stenosis of the aortic valve, that is, aortic stenosis.

[0004] The calcification process in the aortic valve that leads to aortic stenosis begins deep within the aortic valve tissue, near the edge of the attachment site. In advanced disease, nodules spread through the valve stenosis surface. The early stages of the calcification process are called aortic valvular sclerosis, while the later stage, aortic stenosis, occurs when the functional valve area is reduced to the point of causing impaired blood flow.

[0005] Currently, there are no non-invasive treatments available to cure CAVD.

[0006] However, Patent Document 1 discloses that DPP-4 (dipeptidyl peptidase-4) inhibitors such as gliptin can treat aortic valve calcification. DPP-4 (dipeptidyl peptidase-4), also known as CD26 (differentiation antigen group 26), is a protein known to be involved in immunomodulation, apoptosis, and signal transduction. According to the aforementioned U.S. patent, DPP-4 expression increases when blood vessels and valves calcify, and calcification is significantly reduced when a DPP-4 inhibitor is administered, thus disclosing that DPP-4 inhibitors can be usefully used to treat or prevent vascular or valvular diseases. Several types of gliptin-class drugs are disclosed as DPP-4 inhibitors, including sitagliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin, alogliptin, anagliptin, and evogliptin.

[0007] On the other hand, gliflozin is a general term for a group of drugs widely used as SGLT-2 (sodium-glucose cotransporter 2) inhibitors in the treatment of type 2 diabetes. Specifically, dapagliflozin, ertugliflozin, empagliflozin, canagliflozin, bexagliflozin, tofagliflozin, ipragliflozin, enavogliflozin, and luseogliflozin have been developed. SGLT-2 inhibitors are drugs that inhibit the reabsorption of sodium and glucose in the renal tubules and increase their excretion from the body. Recently, Patent Document 2 disclosed that dapagliflozin is effective in heart failure with reduced ejection fraction.

[0008] However, no drugs have yet been developed to treat stenosis caused by calcification of blood vessels or valves. The inventors have made considerable efforts to develop drugs to prevent or treat such stenosis. As a result, the inventors have found that the combination of glipflozin and gliptin has a synergistic effect in inhibiting calcification of blood vessels or valves compared to gliptin alone or glipflozin alone, and thus completed the present invention. [Prior art documents] [Patent Documents]

[0009] [Patent Document 1] U.S. Patent No. 9,416,196 [Patent Document 2] International Publication No. 2021 / 037400 [Overview of the Initiative]

[0010] The object of the present invention is to provide a novel composition or method for preventing or treating vascular stenosis or valvular stenosis.

[0011] To achieve the above objective, in one aspect of the present invention, the present invention provides a pharmaceutical composition comprising an SGLT-2 inhibitor and a DPP-4 inhibitor for preventing or treating vascular stenosis or valvular stenosis. [Effects of the Invention]

[0012] The pharmaceutical composition according to the present invention enables the prevention or treatment of vascular stenosis or valvular stenosis. [Brief explanation of the drawing]

[0013] [Figure 1a] This figure shows a series of photographs illustrating the degree of calcification in aortic smooth muscle cells treated with various concentrations of gliptin-type drugs, which are DPP-4 inhibitors. [Figure 1b]This figure shows a graph illustrating the degree of calcification quantified by analyzing the results of Figure 1a using absorbance analysis. [Figure 2a] This figure shows a series of photographs illustrating the degree of calcification in aortic smooth muscle cells treated with various concentrations of SGLT-2 inhibitors, specifically gliflozin-class drugs. [Figure 2b] This figure shows a graph illustrating the degree of calcification quantified by analyzing the results of Figure 2a using absorbance analysis. [Figure 3a] This figure shows a series of photographs comparing the degree of inhibition of calcification in calcified aortic smooth muscle cells when treated with evogliptin and dapagliflozin alone and when treated with them in combination. [Figure 3b-3c] This figure shows a graph illustrating the degree of calcification quantified by analyzing the results of Figure 3a using absorbance analysis. [Figure 4a] This figure shows a series of photographs comparing the degree of inhibition of calcification in calcified aortic smooth muscle cells when treated with evogliptin and empagliflozin alone and in combination. [Figure 4b] This figure shows a graph illustrating the degree of calcification quantified by analyzing the results of Figure 4a using absorbance analysis. [Figure 5a] This figure shows a series of photographs comparing the degree of inhibition of calcification in calcified aortic smooth muscle cells when treated with evogliptin and canagliflozin alone and when treated with a combination of both. [Figure 5b] This figure shows a graph illustrating the degree of calcification quantified by analyzing the results of Figure 5a using absorbance analysis. [Figure 6a] This figure shows a series of photographs comparing the degree of inhibition of calcification in calcified aortic smooth muscle cells when treated with evogliptin and ertugliflozin alone and when treated with a combination of these. [Figure 6b] This figure shows a graph illustrating the degree of calcification quantified by analyzing the results of Figure 6a using absorbance analysis. [Figure 7a] This figure shows a series of photographs comparing the degree of inhibition of aortic valve calcification when evogliptin and dapagliflozin are administered alone and in combination in a mouse model in which calcification is induced by administration of vitamin D3. [Figure 7b] This figure shows a graph indicating the degree of aortic valve calcification in samples administered with evogliptin and dapagliflozin each alone and in combination. [Figure 8a] This figure shows a graph indicating the degree of renal calcification in samples administered with evogliptin and dapagliflozin each alone and in combination. [Figure 8b] This figure shows a graph indicating the degree of vascular calcification in samples administered with evogliptin and dapagliflozin each alone and in combination. [Mode for Carrying Out the Invention]

[0014] Hereinafter, the present invention will be described in detail.

[0015] The embodiments of the present invention may be modified into various other forms, and the scope of the present invention is not limited to the embodiments described later. It is fully understood by those skilled in the art having average knowledge in the field that the embodiments of the present invention are provided to describe the present invention more accurately.

[0016] Furthermore, "comprising" of elements throughout the present specification does not exclude other elements, and other elements may be included unless specifically stated otherwise.

[0017] In one aspect of the present invention, the present invention provides a combination of an SGLT-2 inhibitor and a DPP-4 inhibitor for preventing or treating vascular stenosis or valvular stenosis.

[0018] In another embodiment of the present invention, the present invention provides a pharmaceutical composition comprising an SGLT-2 inhibitor and a DPP-4 inhibitor for preventing or treating vascular stenosis or valvular stenosis.

[0019] In another aspect of the present invention, the present invention provides a health functional food composition comprising an SGLT-2 inhibitor and a DPP-4 inhibitor for preventing or improving valvular stenosis.

[0020] In another embodiment of the present invention, the present invention provides a method for preventing or treating vascular stenosis or valvular stenosis by administering an SGLT-2 inhibitor and a DPP-4 inhibitor to a subject in need of them, in an amount effective for the prevention or treatment of vascular stenosis or valvular stenosis.

[0021] In another embodiment of the present invention, the present invention provides a combination of an SGLT-2 inhibitor and a DPP-4 inhibitor for manufacturing a pharmacopoeia for preventing or treating vascular stenosis or valvular stenosis.

[0022] In another embodiment of the present invention, the present invention provides a combination of an SGLT-2 inhibitor and a DPP-4 inhibitor used in the prevention or treatment of vascular stenosis or valvular stenosis.

[0023] In another embodiment of the present invention, the present invention provides a combination formulation comprising an SGLT-2 inhibitor and a DPP-4 inhibitor used in the prevention or treatment of vascular stenosis or valvular stenosis.

[0024] In this specification, SGLT-2 inhibitors include drugs of the gliflozin class, and DPP-4 inhibitors include drugs of the gliptin class. In this specification, drugs of the gliflozin class may be used to refer to SGLT-2 inhibitors, and drugs of the DPP-4 class may be used to refer to drugs of the gliptin class.

[0025] Throughout this specification, the term “combination” refers to a clinical treatment in which a glipflozin-class drug and a gliptin-class drug are administered simultaneously or at different time points for the purpose of preventing or treating vascular stenosis or valvular stenosis. All compositions, methods, uses, combinations, and combination preparations described herein are based on the premise of combination use. Possible details of combination use are described below. Combination preparations include both combinations of individual preparations and compound preparations.

[0026] The following description applies to all embodiments of the present invention, including compositions, methods, uses, combinations, and combination formulations.

[0027] Blood vessels include all blood vessels in the body, specifically the cardiovascular vessels related to the heart, and more specifically, the aorta, vena cava, pulmonary artery, vena cava, and renal artery. Valves include the aortic valve, pulmonary valve, mitral valve, and tricuspid valve, but preferably the aortic valve. Stenosis can occur in patients suffering from cardiovascular diseases such as heart failure and arteriosclerosis, or renal diseases such as chronic renal failure.

[0028] The above-mentioned vascular stenosis or valvular stenosis may be accompanied by calcification of the blood vessels or valves. Vascular calcification occurs in patients with cardiovascular diseases such as heart failure, arteriosclerosis, or atherosclerosis, or in patients with renal diseases such as renal artery sclerosis or renal artery atherosclerosis. Examples of renal diseases include chronic kidney disease.

[0029] Vascular calcification or vascular stenosis that occurs in patients with cardiovascular or renal disease can occur in any blood vessel in the body.

[0030] In this invention, calcification refers to a condition in which calcium is deposited in the heart, lungs, kidneys, blood vessels, or valves, causing hardening of the tissue. As calcification progresses, calcification in the kidneys can lead to kidney disease, narrowing of blood vessels or valves, and calcification in the aortic valve can lead to aortic stenosis.

[0031] Calcification can be categorized into medial calcification or atherosclerotic calcification. Calcified tissue is called calcified tissue. Intima-temperate calcification occurs in association with atherosclerosis. Atherosclerosis begins with the accumulation of lipid-rich macrophages and T lymphocytes on the inner surface of blood vessels or valves, forming a lipid layer, followed by the migration of smooth muscle cells from the media. It is thought that chemodynamic substances that stimulate their migration are produced in the nearby endothelium, activated phagocytic cells, etc.

[0032] The migrating smooth muscle cells proliferate, accumulate fat, and produce extracellular matrix. Calcification occurs in the center of the atherosclerotic plaque.

[0033] Medial calcification occurs independently of atherosclerosis and intima-calcification. Medial calcification in peripheral arteries is called Muckeberg sclerosis and is most commonly observed in elderly diabetic patients. Smooth muscle cells and elastin are known to be involved in the development of calcification.

[0034] While calcification caused by renal failure is reported to be primarily medial calcification occurring in the media, calcification caused by atherosclerosis or atherosclerosis-associated calcification is reported to occur primarily in the intima.

[0035] Furthermore, in patients with kidney disease, more specifically in patients with chronic renal failure or chronic kidney disease, calcification of the kidney itself occurs. Therefore, the composition of the present invention can be used to alleviate or treat chronic kidney disease, more specifically chronic kidney disease accompanied by calcification.

[0036] The stenosis treatable in this invention includes, but is not limited to, stenosis diagnosed clinically, and may also include early-stage sclerosis that has not been clinically diagnosed as stenosis. Stenosis may include stages in which symptoms of fibrosis and / or calcification are observed, preferably stages in which symptoms of calcification are observed. In this invention, “treatment” includes reducing the degree of stenosis in the tissue being treated, thereby slowing the progression of stenosis or restoring the symptoms of stenosis to a normal state. When it is said that the progression of stenosis is slowed, this means, as a relative concept, that the progression of stenosis is significantly slower compared to when the combination therapy according to this invention is not performed, for example, when no treatment is performed, or when a general glipflozin-class drug or gliptin-class drug is administered alone. Slowing the progression of stenosis may mean, for example, delaying its progression by 1%, 2%, 3%, 5%, 10%, 15%, 20%, 30%, 40%, or 50%, and the degree of progression of stenosis can be quantitatively assessed by, for example, blood flow velocity, the degree of calcification, etc.

[0037] When stenosis is accompanied by calcification, treatment includes not only completely restoring the calcification to normal tissue, but also slowing the progression of calcification and reducing the degree of calcification that has already occurred. When it is said that the progression of calcification is slowed, this means, as a relative concept, that the progression of calcification is significantly slower compared to when the combination therapy according to the present invention is not performed, for example, when no treatment is performed, or when a general glipfrozin-class drug or gliptin-class drug is administered alone. Slowing the progression of calcification includes, for example, slowing the rate of increase in the amount of deposited calcium, or the area or weight of calcified tissue, by more than 1%, more than 2%, more than 3%, more than 5%, more than 10%, more than 15%, more than 20%, more than 30%, more than 40%, or more than 50%, as indicators of calcification. Reducing the degree of calcification includes reducing the area of ​​calcified tissue by 1% or more, 2% or more, 3% or more, 5% or more, 10% or more, 15% or more, 20% or more, 30% or more, 40% or more, or 50% or more, based on the area of ​​calcified tissue before commencing concomitant administration of the gliflozin-type drug and the gliptin-type drug according to the present invention.

[0038] For example, a method can be used to quantify the area of ​​calcified tissue by quantifying the stained area observed by staining calcium deposits with Alizarin Red S (ARS) or Fonkossa (VK). In the present invention, "prevent" may include mitigating calcification before it occurs, or preventing the deterioration of calcification during the progression of calcification.

[0039] In the present invention, the gliflozin class of drugs is not specifically limited to SGLT-2 inhibitors, but may include one or more gliflozin class drugs selected from the group consisting of dapagliflozin, erzgliflozin, empagliflozin, canagliflozin, bexagliflozin, tofagliflozin, ipragliflozin, enavogliflozin, and luseogliflozin. The gliptin class of drugs is not specifically limited to DPP-4 inhibitors, but may include one or more gliptin class drugs selected from the group consisting of evogliptin, linagliptin, saxagliptin, and sitagliptin.

[0040] In a specific embodiment of the present invention, the gliflozin-class drug may be dapagliflozin, erzgliflozin, empagliflozin, or canagliflozin, and in another specific embodiment, it may be dapagliflozin.

[0041] In specific embodiments of the present invention, the gliptin-type drug may be evogliptin, linagliptin, sitagliptin, or saxagliptin, and in another specific embodiment, it may be evogliptin.

[0042] In the present invention, gliflozin-type drugs and gliptin-type drugs may be contained in the composition, or administered in a therapeutically effective amount to prevent calcification of blood vessels or valves. The pharmaceutical composition or health functional food composition according to the present invention may be provided not only in a single-dose formulation in which gliflozin-type drugs and gliptin-type drugs are physically mixed, but also in a formulation in which they are manufactured as separate doses and then combined at the time of administration.

[0043] The dosage of glipflozin-type and gliptin-type drugs should preferably be determined so that they are administered in a therapeutically effective amount that is not harmful to the patient.

[0044] The dosage of these drugs can be determined according to body weight, age, sex, health status, diet, frequency of administration, method of administration, excretion, and severity of the disease, and a person skilled in the art can determine the appropriate amount. For example, each of the glipflozin class drugs and the gliptin class drugs can be administered at a dose of 0.01 mg to 500 mg per day, once a day or several times a day, for example, two, three, or four times a day.

[0045] Furthermore, these administration cycles can be determined daily, in cycles of a selected number of days from 2 to 7 days, or in irregular cycles. The duration of administration can range from 2 days to 1 month for short-term administration, from more than 1 month to 3 months for medium-term administration, from more than 3 months to 1 to 3 years for long-term administration, or even for the remainder of life. It is clear that the dosage and administration cycle can vary depending on the number of days of administration.

[0046] A person skilled in the art can determine the therapeutically effective dose ratio of glipflozin to gliptin, for example, based on the weight of the active ingredients, within the ranges of 1:1000-1000:1, 1:500-500:1, 1:100-100:1, 1:50-50:1, 1:10-10:1, 1:5-5:1, and 1:2-2:1 over a certain period of time.

[0047] In the present invention, gliflozin-type drugs and gliptin-type drugs can be administered together simultaneously or at different times. Where it is stated that they are administered simultaneously, this may include not only simultaneous administration in a physically mixed form, but also administration at different times within a range of 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, or 1 hour, during which drug interactions may be possible. The pharmaceutical composition or health functional food composition according to the present invention may be provided not only in a single-dose formulation in which gliflozin-type drugs and gliptin-type drugs are physically mixed, but also in formulations that are manufactured separately for individual doses and then combined at the time of administration. When the compositions of the present invention are provided as individual formulations, they may be administered simultaneously as described above, or at different times. The term “pharmaceutical composition” in the present invention is not intended to have a limited meaning referring only to physically mixed compositions, but rather to indicate its use as a pharmaceutical.

[0048] Even if the drugs are administered at different times, the effects of co-administration can be achieved by adjusting the blood drug profiles to allow the gliflozin and gliptin drugs to interact in the blood, for example, by administering them at different times within a range of more than 6 hours but less than 48 hours apart.

[0049] When administered simultaneously, gliflozin and gliptin can be formulated and used independently. Furthermore, commercially available formulations containing each drug as an active ingredient can be used not only for vascular stenosis or valvular stenosis, but also for other indications.

[0050] When administered simultaneously, the active ingredients of gliflozin-type drugs and gliptin-type drugs can be combined and formulated together, so that both can be included in a single formulation.

[0051] When a drug is formulated independently or in combination, the formulation may be for oral administration, such as tablets, capsules, powders, granules, or suspensions, or it may be formulated in the form of an injectable preparation that can be administered parenterally, but it is preferably formulated for oral administration. These formulations may further contain one or more pharmaceutically acceptable excipients during formulation. These excipients may include at least one selected from the group consisting of excipients (diluents), binders, disintegrants, lubricants, and colorants.

[0052] Compositions according to the present invention can be administered alone or in combination with surgery, hormone therapy, drug therapy, and biological modifiers to prevent or treat calcification of blood vessels or valves.

[0053] When administered simultaneously, a health functional food composition containing both the active ingredient of a glipflozin-type drug and the active ingredient of a gliptin-type drug can be formulated.

[0054] Other components that may be included in the health functional food composition of the present invention are not particularly limited, and the composition may include, for example, various herbal extracts, food additives, or natural carbohydrates as additional components, as found in conventional foods. The composition may further include food additives commonly used in the art, such as flavoring agents, colorants, fillers, and stabilizers.

[0055] In health functional food compositions, it is clear that gliflozin-type drugs and gliptin-type drugs are provided as separate formulations and then used together.

[0056] For the above-mentioned functional health food composition, the dosage, administration cycle, and number of administration days can all be applied as described above.

[0057] The present invention will be described in detail below with reference to the following examples.

[0058] However, the following examples are merely illustrative of the present invention, and the scope of the present invention is not limited thereto. [Examples]

[0059] Example 1: Cell-based in vitro assay Experimental method: 1. Human aortic smooth muscle cells (HASMCs) were placed in a 48-well plate at a rate of 1 × 10⁶ per well. 4 The seeds were seeded individually.

[0060] 2. The cells were cultured for 3 days until the cell density reached approximately 80%.

[0061] 3.3 days later, the cell density was checked to confirm that it was approximately 80%.

[0062] 4. A bone formation medium (OM) was prepared to induce calcification in HASMCs. The medium composition was prepared to contain 10% FBS, 1% penicillin-streptomycin, and 3 mM CaCl2 in DMEM (Dulbecc's Modified Essential Medium) (high glucose).

[0063] 5. Solutions were prepared by adding DPP-4 inhibitors (evogliptin, sitagliptin, linagliptin, saxagliptin) and SGLT-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, erzgliflozin) to the OM prepared above, either individually or in combination, at various concentrations.

[0064] For gliptin alone, treatment was performed with the drug at concentrations of 10 μM, 25 μM, 50 μM, and 100 μM (only saxagliptin was treated at concentrations of 2 μM, 5 μM, 10 μM, and 20 μM), and for gliflozin alone, treatment was performed with the drug at concentrations of 10 μM, 20 μM, 30 μM, and 40 μM.

[0065] To compare the effects of combination therapy, patients were treated with evogliptin alone at concentrations of 10 μM and 25 μM, with dapagliflozin alone at concentrations of 1 μM, 5 μM, 10 μM, 20 μM, 30 μM, and 40 μM, and with other gliflozin drugs at concentrations of 10 μM, 20 μM, 30 μM, and 40 μM. Combination therapy was then performed by combining these concentrations.

[0066] 6. Wells appropriate for each group were treated with the drug solution.

[0067] 7. Every other day, a solution containing the drug was prepared in OM, and the wells were treated with this solution.

[0068] 8. Twelve days after treatment with the drug solution, the degree of calcification was determined by staining with alizarin red.

[0069] 9. To quantitatively compare and analyze the degree of calcification, a 10% cetylpyridinium chloride solution was dispensed into each well.

[0070] 10. The reaction was carried out on a shaker for 30 minutes to elute the alizarin red solution from each well.

[0071] 11. Absorbance was measured at a wavelength of 540 nm using a reader to compare the degree of calcification. Results were normalized based on OM without any drug treatment as a control.

[0072] result: The results of monotherapy and combination therapy with gliptin-type drugs and glipflozin-type drugs are shown in the figure.

[0073] In the figure, Evo represents evogliptin, Lina represents linagliptin, Sita represents sitagliptin, Saxa represents saxagliptin, Dapa represents dapagliflozin, Empa represents empagliflozin, Cana represents canagliflozin, Ertu represents erzgliflozin, and OM represents a control without drug treatment in the cell culture medium.

[0074] Absorbance was measured and normalized against the control along with the staining results.

[0075] Figures 1a and 1b show the results of treatment with gliptin-type drugs, which are DPP-4 inhibitors, at various concentrations. All of them were confirmed to inhibit calcification in a concentration-dependent manner.

[0076] Figures 2a and 2b show the results of treatment with gliflozin-class drugs, which are SGLT-2 inhibitors, at various concentrations. All of them were confirmed to inhibit calcification in a concentration-dependent manner.

[0077] Figures 3a to 6b show the degree of inhibition of calcification when treated with DPP-4 inhibitors and SGLT-2 inhibitors alone and in combination.

[0078] When evogliptin and dapagliflozin were used together, a synergistic anticalcification effect was observed compared to either treatment alone.

[0079] When evogliptin and empagliflozin were used together, a synergistic anticalcification effect was observed compared to either treatment alone.

[0080] When evogliptin and canagliflozin were used together, a synergistic anticalcification effect was observed compared to either treatment alone.

[0081] When evogliptin and ertugliflozin were used together, a synergistic anticalcification effect was observed compared to either treatment alone.

[0082] Example 2: In vivo mouse model assay Experimental method: 1. Preparation of Vitamin D3 Solution Add the exact weight of vitamin D3 (6.5 × 10¹⁶) to a solution of 30% PEG400, 0.5% Tween80, 5% propylene glycol, and 64.5% physiological saline. 4 A vitamin D3 solution was obtained by dissolving IU / ml (1.625 mg / ml) by sonication for 1 hour.

[0083] 2. Preparation of gliptin and glipflozin All materials were accurately weighed and dissolved or dispersed in 0.5% CMC sodium salt to prepare evogliptin at 1 mg / kg / 100 μl and dapagliflozin at 2 mg / kg / 100 μl.

[0084] 3. Preparing the animals (mice) Animal: C57BL / 6 mouse (OrientBio, Seongnam City, South Korea) Gender: Male Age upon arrival: C57BL / 6 (6 weeks old) Rearing: The animals were reared in a sterile cleanroom with controlled temperature (25°C) and humidity (45%-55%) in polycarbonate cages with filter caps (each cage holding 10 animals). The light-dark cycle was 12 hours:12 hours, and sterile food and water were provided free of charge.

[0085] Guidelines: All animals were handled in accordance with the guidelines of the Daegu Haany University Institutional Animal Care and Use Committee (Gyeongsan, South Korea).

[0086] 4. In vivo drug administration: A mouse model of calcification induced by vitamin D administration. After a one-week acclimatization period, the mice were randomly divided into 18 groups.

[0087] In all groups of mice, vitamin D3 (6.5 × 10) was administered. 5IU / kg was administered subcutaneously every 24 hours for 3 days. Simultaneously, the non-pharmacologically treated group (excluding those affected) received 0.5% CMC orally, and gliptin and gliflozin were administered orally individually or in combination at 1-hour intervals depending on the concentration. After 7 days, the complete heart, kidney, and aorta were resected and isolated under anesthesia. The resected heart was preserved in buffered formalin until further histopathological and histomorphological examinations.

[0088] 5. Analysis of aortic valve calcification Each cardiac specimen was transversely sectioned in a single section near the origin / root region of the ascending aorta. Histological sections were then prepared from all 180 specimens received. All transverse sections of the cardiac aortic valve were re-fixed in 10% neutral buffered formalin for 24 hours to prepare histological specimens. After embedding the specimens in paraffin, two serial sections 3 μm–4 μm thick were prepared on each paraffin block and stained with hematoxylin and eosin (HE) for general histopathological examination, or with von Kossa (VK) for calcium deposition.

[0089] In histopathological analysis, the average calcification area of ​​the aortic valve (% / mm²) was determined from VK staining. 2 The group distribution was calculated. The histopathologists were not informed of the group distribution when this analysis was performed. Histopathological examination of one section, cross-section, and histological region of each cardiac aortic valve was performed, and a total of 180 cardiac samples from C57BL / 6 mice from each group were statistically analyzed.

[0090] 6. Analysis of renal and aortic calcification Individual kidney samples were analyzed using the left kidney, and the aorta was analyzed using the descending aorta. The excised left kidney and descending aorta were each diluted 10 times with chilled physiological saline, homogenized using a homogenizer, and stored in 0.6N HCl at 4°C for 24 hours to separate calcium from the tissue. The supernatant was then separated using a refrigerated centrifuge, and the amount of calcium in the supernatant was measured. For accurate measurement, quantification was performed based on the amount of protein.

[0091] result: The results of monotherapy and combination therapy with gliptin-type drugs and glipflozin-type drugs are shown in the figure.

[0092] In the diagram, Evo represents evogliptin, DaPa represents dapagliflozin, and Disease represents the non-pharmacological treatment group.

[0093] Figures 7a and 7b show the degree of inhibition of aortic valve calcification in a mouse model of vitamin D3-induced calcification when evogliptin and dapagliflozin were administered alone and in combination. When evogliptin and dapagliflozin were administered together, a synergistic anticalcification effect was observed compared to either treatment alone.

[0094] Figures 8a and 8b show the degree of inhibition of renal and aortic calcification in a mouse model of vitamin D3-induced calcification when evogliptin and dapagliflozin were administered alone and in combination.

[0095] As demonstrated in the results for aortic valve calcification, a synergistic anticalcification effect was observed when evogliptin and dapagliflozin were used together, compared to either treatment alone.

[0096] Based on the experimental results described above, it can be concluded that the pharmaceutical composition comprising the SGLT-2 inhibitor and the DPP-4 inhibitor according to the present invention, when administered in combination, can suppress calcification of the kidneys, blood vessels, or valves, and treat renal disease, vascular stenosis, or valvular stenosis more effectively than when each is administered alone.

Claims

1. A pharmaceutical composition comprising a glipflozin-type drug and a gliptin-type drug for preventing or treating renal disease or vascular stenosis or valvular stenosis.

2. The pharmaceutical composition according to claim 1, wherein the valve includes an aortic valve.

3. The pharmaceutical composition according to claim 1, wherein the vascular stenosis or valvular stenosis is accompanied by calcification of blood vessels or valves, and the kidney disease is accompanied by calcification of kidneys.

4. The pharmaceutical composition according to claim 3, wherein the calcification of the blood vessel or valve is caused by arteriosclerosis or atherosclerosis.

5. The pharmaceutical composition according to claim 3, wherein the calcification of blood vessels or kidneys occurs in patients suffering from kidney disease.

6. The pharmaceutical composition according to claim 1, wherein the aortic stenosis includes calcific aortic valve disease (CAVD).

7. The pharmaceutical composition according to claim 1, wherein the gliflozin-type drug is at least one selected from the group consisting of dapagliflozin, erzgliflozin, empagliflozin, canagliflozin, bexagliflozin, tofagliflozin, ipragliflozin, enabogliflozin, and luseogliflozin.

8. The pharmaceutical composition according to claim 1, wherein the gliptin-type drug is at least one selected from the group consisting of evogliptin, linagliptin, saxagliptin, and sitagliptin.

9. The pharmaceutical composition according to claim 1, wherein the gliflozin-type drug is one selected from the group consisting of dapagliflozin, erzgliflozin, empagliflozin, canagliflozin, bexagliflozin, tofagliflozin, ipragliflozin, enavogliflozin, and luseogliflozin, and the gliptin-type drug is one selected from the group consisting of evogliptin, linagliptin, saxagliptin, and sitagliptin.

10. The pharmaceutical composition according to claim 1, wherein the gliflozin-type drug and the gliptin-type drug are administered together.

11. The pharmaceutical composition according to claim 1, wherein the gliflozin-type drug and the gliptin-type drug are administered simultaneously or at different times.

12. The pharmaceutical composition according to claim 1, provided as a combination compound.

13. A combination compound for preventing or treating kidney disease or vascular stenosis or valvular stenosis, comprising a composition containing a glipflozin-type drug and a composition containing a gliptin-type drug, wherein each composition is used in combination.

14. A method for preventing or treating renal disease, vascular stenosis, or valvular stenosis by administering glipflozin-type drugs and gliptin-type drugs in amounts effective for the prevention or treatment of renal disease, vascular stenosis, or valvular stenosis to subjects who require such prevention or treatment.

15. The method according to claim 14, wherein the gliflozin-type drug and the gliptin-type drug are administered simultaneously or at different time points.

Citation Information

Patent Citations

  • Composition for prophylaxis or treatment of vascular or cardiac valvular calcification comprising dipeptidyl peptidase-4 inhibitor

    US9416196B2

  • Methods of treating heart failure with reduced ejection fraction with dapagliflozin

    WO2021037400A1